GA101 vs. Rituximab (Gallium) in advanced indolent NHL (#429)
Laufzeit: 01.01.2011 - 31.12.2021
imported
Kurzfassung
A multicenter, phase III, open-label, randomized study in previously untreated patients with advanced indolent NHL evaluating the benefit of GA101 (RO5072759) plus chemotherapy compared with Rituximab plus chemotherapy followed by GA101 or Rituximab maintenance therapy in responders
